Fig 1: CRISPR-mediated deletion of dystroglycan (Dag1) in the OB decreases inhibitory GC?MC synaptic transmission by suppressing the release probability.a Experimental design. The OB of constitutive CAS9-expressing mice was infected stereotactically with AAVs encoding control or Dag1 gRNAs together with tdTomato at P15-18. Mice were analyzed 2–3 weeks later. b Representative fluorescence images of OB sections stained for the inhibitory synapse marker gephyrin (green) and tdTomato expressed via AAVs (red). c, d Dystroglycan (Dag1) deletion does not change the density or size of gephyrin-positive synaptic puncta (c, sample images; d, summary of puncta densities (top) and size (bottom)). e Representative image of a mitral cell filled with neurobiotin (blue) via the patch pipette (tdTomato expressed via AAVs is shown in red, and EGFP expressed via the CAS9 knockin in green). f–h Dystroglycan deletion decreases the mIPSC frequency monitored in mitral cells (f, representative mIPSC traces recorded in the presence of TTX; g, cumulative probability of the interevent interval and summary of the mIPSC frequency; h, cumulative probability and summary of the mIPSC amplitudes). i–k Dystroglycan deletion suppresses inhibitory GC?MC synaptic transmission evoked by extracellular stimulation, as documented by input/output curves (i, representative IPSC traces; j, summary of input/output amplitudes; k, summary of the slope of the input/output curves). l Dystroglycan deletion increases the coefficient of variation of evoked IPSCs at GC?MC synapses, suggesting a decrease in release probability. m, n Dag1 deletion induces a large increase in the paired-pulse ratio (m, representative traces; n, summary of the paired-pulse ratio). Numerical data are means ± SEM; n’s (animals (d) and cells/experiments (the rest)) are indicated in the summary graph bars (d) or above the sample traces (f, i and m) and apply to all graphs in an experimental series with b–d belonging to the same series. Statistical analyzes were performed using two-tailed unpaired t-test in d, g, h, k, l and two-way ANOVA in j & n with Bonferroni multiple comparison test, with *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Source data and statistical results for all experiments are provided within the Source Data file.
Fig 2: CRISPRi-mediated inhibition of dystroglycan expression in dissociated OB neurons suppresses inhibitory but not excitatory synaptic transmission, with the Nrxn3 and dystroglycan manipulations each occluding the other’s phenotype.a–c CRISPR interference (CRISPRi)-mediated inhibition of dystroglycan (Dag1) expression decreases the levels of dystroglycan mRNAs and significantly decreases the amplitude of evoked IPSCs (a, qRT-PCR measurements of Dag1 mRNA levels; b, sample traces; c, summary graph of IPSC amplitudes). d–f Combined inhibition of dystroglycan (Dag1) and Nrxn3 expression does not lower the evoked IPSC amplitude more severely than the single inhibition of either dystroglycan or of Nrxn3 expression (d, sample traces; e, f, summary graphs of the IPSC amplitudes (e) and charge transfer (f)). IPSCs evoked by extracellular stimulation were recorded from mitral/tufted cells in dissociated culture obtained from Nrxn3 cKO mice that were infected with lentiviruses expressing either ?Cre and/or the Dag1 CRISPRi components. g–i The single or double inhibition of dystroglycan (Dag1) and Nrxn3 expression have no effect on evoked NMDAR- and AMPAR-EPSC amplitudes (g, sample traces; h, i summary graphs of the evoked NMDAR-EPSC amplitudes (h) and AMPAR-EPSC amplitudes (i)). Experiments were performed as in d–f. Numerical data are means ± SEM; n’s (cells/experiments) are indicated above the sample traces and apply to all graphs in an experimental series. Statistical analyzes were performed with a one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test (e, f, h, and i), a two-tailed one sample t test (a), or a unpaired two-tailed t test (c), with *p < 0.05, **p < 0.01, and ***p < 0.001. Source data and statistical results for all experiments are provided within the Source Data file.
Fig 3: Dystroglycan (Dag1) deletion in mitral cells of the OB and in the mPFC suppresses inhibitory synaptic transmission.a Mitral cells are infected with control or Dag1 gRNAs and tdTomato by projection-specific labeling through retro-AAVs injected in the piriform cortex. b Representative OB sections stained for gephyrin (green) and for tdTomato (red). c, d Dystroglycan deletion does not change the density or size of gephyrin-positive synapses (green) co-localized with tdTomato-expressing mitral cells (c, sample images; d, summary of puncta densities (top) and puncta size (bottom)). e Representative image of a mitral cell filled with neurobiotin (blue) and expressing tdTomato via AAVs (red). f–h Dystroglycan (Dag1) deletion decreases the mIPSC frequency in mitral cells (f, representative mIPSC traces; g, h cumulative probability of the mIPSC interevent intervals and amplitudes, insets: summary of the mIPSC frequency and amplitudes). i–k Dystroglycan (Dag1) deletion suppresses the IPSC amplitude at GC?MC synapses (i, representative IPSC traces; j, summary of input/output amplitudes; k, summary of the input/output curve slopes). l Mitral cell-specific dystroglycan (Dag1) deletion increases the coefficient of variation of evoked IPSCs. m, n Dystroglycan (Dag1) deletion induces a large increase in the paired-pulse ratio (m, representative traces; n, summary plot of the paired-pulse ratio). o–r Dystroglycan deletion in the mPFC decreases the mIPSC frequency monitored in Layer 5 pyramidal neurons (o, representative image of an mPFC section; p, representative mIPSC traces; q–r, cumulative probability of the mIPSC interevent intervals and amplitudes, insets: summary of the mIPSC frequency and amplitudes)). Numerical data are means ± SEM; n’s (animals (d) or cells/experiments (the rest)) are indicated in the summary graph bars (d) or above the sample traces (f, i, m, and p) and apply to all graphs in an experimental series with b–d belonging to the same series. Statistical analyzes were performed using two-tailed unpaired t-test in d, g, h, k, l, q, r, and by two-way ANOVA in j & n with Bonferroni multiple hypothesis testing, with *p < 0.05, **p < 0.01, and ***p < 0.001. Source data and statistical results for all experiments are provided within the Source Data file.
Supplier Page from Abcam for Anti-Alpha Dystroglycan antibody [45-3]